The effectiveness and safety of administering antiplatelet medications following reperfusion therapy in patients with ischemic stroke

TAT may enhance neurological recovery but increases bleeding risk. Patient selection and monitoring are crucial, and long-term studies are needed to fully evaluate its risk-benefit profile.